

Enrico Berrino

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/827083/publications.pdf>

Version: 2024-02-01

24
papers

552
citations

759233

12
h-index

713466

21
g-index

27
all docs

27
docs citations

27
times ranked

741
citing authors

#	ARTICLE	IF	CITATIONS
1	Evolving concepts in HER2 evaluation in breast cancer: Heterogeneity, HER2-low carcinomas and beyond. <i>Seminars in Cancer Biology</i> , 2021, 72, 123-135.	9.6	162
2	Basic principles of biobanking: from biological samples to precision medicine for patients. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 479, 233-246.	2.8	67
3	The Multifaceted Nature of Tumor Microenvironment in Breast Carcinomas. <i>Pathobiology</i> , 2020, 87, 125-142.	3.8	49
4	Next-Generation Sequencing Approaches for the Identification of Pathognomonic Fusion Transcripts in Sarcomas: The Experience of the Italian ACC Sarcoma Working Group. <i>Frontiers in Oncology</i> , 2020, 10, 489.	2.8	38
5	Acid-free glyoxal as a substitute of formalin for structural and molecular preservation in tissue samples. <i>PLoS ONE</i> , 2017, 12, e0182965.	2.5	27
6	Cold Formalin Fixation Guarantees DNA Integrity in Formalin Fixed Paraffin Embedded Tissues: Premises for a Better Quality of Diagnostic and Experimental Pathology With a Specific Impact on Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 173.	2.8	22
7	The expression of LINE1<i>MET</i> chimeric transcript identifies a subgroup of aggressive breast cancers. <i>International Journal of Cancer</i> , 2018, 143, 2838-2848.	5.1	21
8	Establishment and Characterization of a New Intrahepatic Cholangiocarcinoma Cell Line Resistant to Gemcitabine. <i>Cancers</i> , 2019, 11, 519.	3.7	21
9	The Dilemma of HER2 Double-equivocal Breast Carcinomas. <i>American Journal of Surgical Pathology</i> , 2018, 42, 1190-1200.	3.7	20
10	Oxidative DNA damage induces hypomethylation in a compromised base excision repair colorectal tumourigenesis. <i>British Journal of Cancer</i> , 2017, 116, 793-801.	6.4	17
11	Pazopanib and Trametinib as a Synergistic Strategy against Osteosarcoma: Preclinical Activity and Molecular Insights. <i>Cancers</i> , 2020, 12, 1519.	3.7	15
12	COVseq is a cost-effective workflow for mass-scale SARS-CoV-2 genomic surveillance. <i>Nature Communications</i> , 2021, 12, 3903.	12.8	14
13	Whole exome sequencing in the differential diagnosis of Diamond-Blackfan anemia: Clinical and molecular study of three patients with novel RPL5 and mosaic RPS19 mutations. <i>Blood Cells, Molecules, and Diseases</i> , 2017, 64, 38-44.	1.4	12
14	Castration-Induced Downregulation of SPARC in Stromal Cells Drives Neuroendocrine Differentiation of Prostate Cancer. <i>Cancer Research</i> , 2021, 81, 4257-4274.	0.9	11
15	Evaluation of global and intragenic hypomethylation in colorectal adenomas improves patient stratification and colorectal cancer risk prediction. <i>Clinical Epigenetics</i> , 2021, 13, 154.	4.1	11
16	Collision of germline POLE and PMS2 variants in a young patient treated with immune checkpoint inhibitors. <i>Npj Precision Oncology</i> , 2022, 6, 15.	5.4	11
17	MiR-100 is a predictor of endocrine responsiveness and prognosis in patients with operable luminal breast cancer. <i>ESMO Open</i> , 2020, 5, e000937.	4.5	10
18	Pursuit of Gene Fusions in Daily Practice: Evidence from Real-World Data in Wild-Type and Microsatellite Instable Patients. <i>Cancers</i> , 2021, 13, 3376.	3.7	8

#	ARTICLE	IF	CITATIONS
19	PIK3R1W624R Is an Actionable Mutation in High Grade Serous Ovarian Carcinoma. <i>Cells</i> , 2020, 9, 442.	4.1	7
20	Colorectal Adenomatous Polyposis: Heterogeneity of Susceptibility Gene Mutations and Phenotypes in a Cohort of Italian Patients. <i>Genetic Testing and Molecular Biomarkers</i> , 2016, 20, 777-785.	0.7	5
21	The ACC melanoma pilot project: "Real-world" evaluation of an NGS platform for molecular characterization of melanoma in Italy.. <i>Journal of Clinical Oncology</i> , 2019, 37, e14600-e14600.	1.6	0
22	Antitumor activity of pazopanib (P) and trametinib (T) in preclinical models of osteosarcoma (OS).. <i>Journal of Clinical Oncology</i> , 2019, 37, e22509-e22509.	1.6	0
23	PARP1 Inhibitor and Trabectedin Combination Does Not Increase Tumor Mutational Burden in Advanced Sarcomas" A Preclinical and Translational Study. <i>Cancers</i> , 2021, 13, 6295.	3.7	0
24	The Tumor-Specific Expression of L1 Retrotransposons Independently Correlates with Time to Relapse in Hormone-Negative Breast Cancer Patients. <i>Cells</i> , 2022, 11, 1944.	4.1	0